Overall, our study provided novel information on the spectrum of DDR pathway activity that occurs in CLL from a total and phosphor-protein perspective, the clinical relevance of the expression subgroups and individual proteins, and provided implications for cell signaling that may be interconnected with DDR protein activity; upon further investigation, this information could lead to the discovery of additional therapeutic targets for optimizing the current treatment paradigm for relapsed and refractory patients. The gene discussed is DDR1; the disease is B-cell chronic lymphocytic leukemia.